07:00 , May 24, 2010 |  BC Week In Review  |  Clinical News

3M Rapid Detection RSV Test regulatory update

Health Canada approved Response Biomedical's RAMP Respiratory Syncytial Virus (RSV) assay under a Class 3 (near patient/point-of-care) medical device license to detect the presence of RSV F-protein antigens in nasopharyngeal swab, nasopharyngeal aspirate or nasal...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Company News

3M sales and marketing update

3M launched its 3M Rapid Detection RSV Test to identify the presence of the respiratory syncytial virus (RSV) antigen. The qualitative immunochromatographic assay runs on the RAMP platform from Response Biomedical Corp. (TSX:RBM; OTCBB:RPBIF, Vancouver,...
07:00 , May 4, 2009 |  BC Week In Review  |  Clinical News

3M Rapid Detection RSV Test regulatory update

Response Biomedical submitted a 501(k) application to FDA for its 3M Rapid Detection RSV Test to identify the presence of the respiratory syncytial virus (RSV) antigen. The qualitative immunochromatographic assay runs on Response Biomedical's RAMP...
08:00 , Jan 12, 2009 |  BioCentury  |  Finance

2009 milestones

2009 milestones...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Clinical News

3M Rapid Detection RSV Test: Pivotal trial started

The company began a North American pivotal study to compare its RAMP 3M Rapid Detection RSV Test to standard laboratory culture and Direct Fluorescence Staining Assay (DFSA). Response Biomedical Corp. (TSX-V:RBM; OTCBB:RPBIF), Vancouver, B.C.  ...